Archbishop Carlo Maria Viganò, a former Vatican ambassador to the U.S. and outspoken adversary of Pope Francis, made waves in the QAnon world on Friday.
Archbishop Carlo Maria Viganò, a former Vatican ambassador to the U.S. and outspoken adversary of Pope Francis, made waves in the QAnon world on Friday.
The High-voltage Power Cable Market will grow by USD 13.63 bn during 2020-2024
Thai police will deploy nearly 6,000 officers on Wednesday for a demonstration at the office that manages the royal fortune by protesters demanding that King Maha Vajiralongkorn give up personal control of the assets. Police said on Tuesday that no protesters would be allowed within 150 metres (450 feet) of the Crown Property Bureau, where royalists have also said they plan to gather in defence of a monarchy that faces its biggest challenge in decades. "Depending on how protesters behave, we will take appropriate measures," he told a news conference.
Star condemned Trump for refusing to concede
China’s latest trip to the moon is another milestone in the Asian powerhouse’s slow but steady ascent to the stars. China became the third country to put a person into orbit a generation ago and the first to land on the far side of the moon in 2019. Future ambitions include a permanent space station and putting people back on the moon more than 50 years after the U.S. did.
‘Alex believed in the importance of Jeopardy and always said that he wanted the show to go on after him,’ executive producer Mike Richards said
NEW YORK — David Dinkins, whose historic 1989 victory as New York City's first and only black mayor was quickly eclipsed by rising crime and racial turmoil that doomed his re-election, died Monday at his home, police said. He was 93. His death comes a little more than a month after his wife, Joyce, passed away on Oct. 11. Dinkins, in his two decades after leaving City Hall, kept a busy ...
The Chinese Uber for trucks Manbang announced Tuesday that it has raised $1.7 billion in its latest funding round, two years after it hauled in $1.9 billion from investors including SoftBank Group and Alphabet Inc's venture capital fund CapitalG. The news came fresh off a Wall Street Journal report two weeks ago that Manbang was seeking $1 billion ahead of an initial public offering next year. The company declined to comment on the matter, though its CEO Zhang Hui said in May 2019 that the firm was "not in a rush" to go public.
‘Scotland will not be the last country to make period poverty history — but it now has a chance to be the first’
David Dinkins, who has died aged 93, served as the city's first and only black mayor from 1990-1993.
Save on comforter and comforter set deals at the Black Friday sale, featuring down, quilted, and reversible comforter, duvet, and duvet set deals
China on Tuesday reported two new coronavirus cases in the cities of Shanghai and Tianjin as it seeks to prevent small outbreaks from becoming larger ones. The National Health Commission said that there were two new locally spread cases in the previous 24-hour period, one in each city. It also reported 20 cases among people who had arrived from overseas.
The Puerto Rican star canceled his performance at last night’s AMAs but did appear remotely to present the award for favorite Latin female artist
With less than a week to go until the big day, the giant retailer has begun its countdown with more impressive offers
(Bloomberg) -- Credit Suisse Group AG expects to book a $450 million impairment charge on its stake in York Capital Management as the U.S. firm winds down most of its hedge fund strategies.The charge, which could still change, will be booked in the fourth quarter, the Zurich-based bank said Tuesday. Credit Suisse agreed in 2010 to take a stake of about 30% in the firm founded by Jamie Dinan, offering to pay at least $425 million to give clients access to its investments.The charge adds to a series of setbacks and missteps at Credit Suisse this year, ranging from losses on loans to wealthy clients to lackluster trading results, as the market volatility caused by the coronavirus pandemic rattles businesses across the bank. Chief Executive Thomas Gottstein, who took over in February, has been cleaning up the business and restructuring in an effort to simplify the bank.The asset management business is one of the units that have struggled in this year’s volatility. Credit Suisse has been closing down funds and laying off employees at its alternative asset management business. Actions include shuttering a quantitative fund and taking a 24 million Swiss franc ($26 million) charge on seed capital in a U.S. real estate fund in the third quarter, Chief Financial Officer David Mathers said in a recent interview.Gottstein said in September that the bank is planning a strategic review of asset management over the next 12 months. For now, he has ruled out a sale or merger.Credit Suisse’s asset management operation is split between a more traditional business with long equity and fixed-income strategies sold largely to its private banking clients, and an alternative asset management business in the U.S. consisting of wholly owned hedge funds, a large credit business and a number of smaller funds and external investments.Credit Suisse said the charge on York Capital will reduce a key measure of capital strength, the so-called common equity Tier 1 ratio, by 7 basis points this quarter, but won’t change that bank’s plans to return capital to shareholders.York, started in 1991, is winding down most of its hedge fund business and retooling to focus on long-term products after “a year marked by tremendous upheaval and disruption,” according to a letter to clients. Co-Chief Investment Officer Christophe Aurand will be leaving and William Vrattos will take over as sole CIO, Chief Executive Officer Dinan wrote in the letter seen by Bloomberg News.Dinan has seen the firm’s assets tumble from their $26 billion peak in 2015.(Adds Credit Suisse asset management changes in 4th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The Gamecocks bring back a core of AJ Lawson, Keyshawn Bryant, Jermaine Couisnard and Justin Minaya from a lineup that went 18-13 in 2019-20. "We return our whole team, yet no one speaks about us," South Carolina coach Frank Martin said in his Monday media availability. Since reaching the Final Four in 2017, South Carolina fell short of winning 20 games in the three subsequent seasons.
Australia's A-League is set to kick off next month with organizers predicting domestic borders will be open and the only club that needs to be relocated because of COVID-19 restrictions is the New Zealand-based Wellington Phoenix. The soccer season schedule was released Tuesday and features games in four states in the opening two rounds, expanding to Western Australia in the third. Western Sydney Wanderers will get the season started against expansion club Macarthur FC in Parramatta on Dec. 27, and defending champion Sydney FC will open against Melbourne City on Dec. 30.
‘If you’re telling a story about a community and they’re not welcoming to you, then f*** off,’ said star
The best weighted blanket deals for Black Friday 2020, featuring cooling blanket and 20lb, 18lb, and more weighted blanket offersBlack Friday experts are comparing the best weighted blanket deals for Black Friday 2020, including savings on cooling blankets and weighted blankets for kids (5lb, 7lb, and 10lb blankets) and adults (20lb, 18lb, 15lb, and 12lb blankets). Links to the top deals are listed below.Best Weighted Blanket Deals: * Save up to 20% on hypoallergenic weighted blankets & bundles at Purple.com \- check the latest prices of weighted blankets suitable for queen and king bed sizes and includes free shipping * Save up to 40% on weighted blankets for adults & kids at Walmart \- check the latest deals on a wide range of 18lb, 20lb, 7ln, 12lb & 15lb standard and cooling weighted blankets * Save up to 25% on a wide range of weighted blankets at Overstock.com \- check the latest savings on cotton, faux fur, fleece, and cooling weighted blankets * Save up to $35 on weighted blankets for kids and adults at Target.com \- check live prices on 12-lb, 15-lb, 18-lb, and 20-lb weighted blankets * Save up to 37% on weighted blankets including 20lb, 18lb & more at Amazon \- click the link for the latest savings on cotton, down, fleece & more cooling & weighted blankets for kids and adults * Save on weighted blankets at Tempur-Pedic \- check the live prices on 15-lb and 20-lb weighted blankets * Save up to 50% on kids weighted blankets at Amazon \- check the latest deals on 5 lb, 7lb & 10lb weighted blankets, cooling weighted blankets for boys & girls, including hypoallergenic & water-resistant fabric options * Save up to 32% on cooling weighted blankets for adults & kids at Amazon \- available in 20 lb, 18lb, 15lb, 12lb, 10lb, 7lb & 5lb cooling weighted blanket sizes Looking for more deals? Click here to view the entire selection of live deals at Walmart’s Black Friday sale and click here to see Amazon’s latest Black Friday deals. Save Bubble earns commissions from purchases made using the links provided.About Save Bubble: Save Bubble round-up the latest online sales news. As an Amazon Associate and affiliate Save Bubble earns from qualifying purchases. Contact: Andy Mathews (firstname.lastname@example.org)
Adverty AB (publ) has been granted a patent by the United States Patent and Trademark Office for its in-game ad viewability technology BrainImpression™; a groundbreaking method for determining ad viewability and impressions within complex gaming environments. The patented invention is one of the core functionalities of Adverty's leading in-game advertising platform.
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Diabetes Drug Delivery Devices Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering. The "Diabetes Drug Delivery Devices Market, 2020-2030" report features an extensive study of the current market landscape and the likely adoption of diabetes drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain. One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for diabetes drug delivery devices. Based on multiple parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall diabetes drug delivery devices market with a detailed market segmentation on the [A] type of device (pen-injectors, insulin pumps, conventional syringes and others), [B] route of administration (subcutaneous, intravenous and others), [C] diabetes type (type 1 diabetes and type 2 diabetes), [D] device usability (disposable and reusable) and [E] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution. Amongst other elements, the report includes: * An overview of the current market landscape of diabetes drug delivery devices available for delivery of insulin and non-insulin drugs, including information on device specifications, such as type of device (insulin pump, pen-injector/autoinjector, jet injector, microneedle patch, nasal delivery system, insulin port, oral delivery system and inhalation device), stage of development (marketed, clinical and preclinical), route of administration (subcutaneous, intramuscular, transdermal, oral, intranasal and others), mode of drug delivery (invasive, minimally invasive and non-invasive), needle attributes (needleless, detachable needle, cannula, hidden needle and fixed needle), type of drug delivery system (mechanical method and electrical method), drug administration speed (fast and slow), device usability (disposable, reusable and reusable (disposable components)), diabetes type (type I diabetes, type II diabetes and diabetes type (unspecified)) and type of drug (insulin and non-insulin). In addition, the report present the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size and location of headquarters. * A detailed competitiveness analysis of diabetes drug delivery devices based on various relevant parameters, such as supplier power (based on the experience/expertise of the developer) and product specifications (type of device, route of administration, diabetes type, needle attributes, availability of needle safety system, self-administration potential, mode of drug delivery, device usability, drug administration speed and development stage). * An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering technology integration agreements, product development agreements, distribution agreements, acquisitions, product commercialization agreements, supply agreements, licensing agreements, product development and commercialization agreements and other relevant types of deals. * Elaborate profiles of the prominent players developing diabetes drug delivery devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. * A review of recent initiatives undertaken by big pharma players engaged in this domain. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues of 2019), based on their initiatives related to diabetes drug delivery devices.Key Topics Covered:1\. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2\. EXECUTIVE SUMMARY 3\. INTRODUCTION 3.1. Chapter Overview 3.2. An Overview of Diabetes 3.2.1. Classification of Diabetes 188.8.131.52. Type 1 Diabetes 184.108.40.206. Type 2 Diabetes 3.3. Route of Administration for Diabetes Drugs 3.3.1. Buccal Route 3.3.2. Inhalation Route 3.3.3. Intradermal Route 3.3.4. Intramuscular Route 3.3.5. Intranasal Route 3.3.6. Oral Route 3.3.7. Subcutaneous Route 3.4. Key Challenges Associated with Delivery of Diabetes Drugs 3.5. Diabetes Drug Delivery Devices 3.5.1. Implants 3.5.2. Inhalation Devices 3.5.3. Insulin Ports 3.5.4. Insulin Pumps 3.5.5. Jet Injectors 3.5.6. Microneedle Patches 3.5.7. Nasal Delivery Devices 3.5.8. Pen-Injectors/Autoinjectors 3.6. Concluding Remarks 4\. CURRENT MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Diabetes Drug Delivery Devices: Overall Market Landscape 4.2.1. Analysis by Type of Device 4.2.2. Analysis by Stage of Development 4.2.3. Analysis by Route of Administration 4.2.4. Analysis by Mode of Drug Delivery 4.2.5. Analysis by Needle Attributes 4.2.6. Analysis by Type of Drug Delivery System 4.2.7. Analysis by Drug Administration Speed 4.2.8. Analysis by Device Usability 4.2.9. Analysis by Diabetes Type 4.2.10. Analysis by Type of Drug 4.3. Diabetes Drug Delivery Devices: List of Developers 4.3.1. Analysis by Type of Developer 4.3.2. Analysis by Year of Establishment 4.3.3. Analysis by Company Size 4.3.4. Analysis by Location of Headquarters 4.3.5. Leading Manufacturers: Analysis by Number of Products 5\. PRODUCT COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Methodology 5.2.1. Product Competitive Analysis: Diabetes Drug Delivery Devices 6\. PARTNERSHIPS AND COLLABORATIONS 6.1. Chapter Overview 6.2. Partnership Models 6.3. Diabetes Drug Delivery Devices: List of Partnerships and Collaborations 6.3.1. Analysis by Year of Partnership 6.3.2. Analysis by Type of Partnership 6.3.3. Analysis by Year and Type of Partnership 6.3.4. Analysis by Type of Device 6.3.5. Most Active Players: Analysis by Number of Partnerships 6.3.6. Geographical Analysis 220.127.116.11. Region-wise Distribution 18.104.22.168. Country-wise Distribution 7\. COMPANY PROFILES 7.1. Chapter Overview 7.2. Bigfoot Biomedical 7.2.1. Company Overview 7.2.2. Diabetes Drug Delivery Device Portfolio 7.2.3. Recent Developments and Future Outlook 7.3. Debiotech 7.4. Haselmeier 7.5. Medtronic 7.6. Novo Nordisk 7.7. Roche 7.8. SOOIL 7.9. Ypsomed 8\. DIABETES DRUG DELIVERY DEVICES RELATED INITIATIVES OF BIG PHARMA PLAYERS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Initiatives of Big Pharma Players 8.3.1. Analysis by Diversity in Device Portfolio 8.3.2. Analysis by Phase of Development 8.3.3. Analysis by Diabetes Type 8.3.4. Analysis by Type of Drug 8.3.5. Analysis by Number of Partnerships 8.4. Benchmark Analysis of Big Pharma Players 9\. MARKET SIZING AND OPPORTUNITY ANALYSIS 9.1. Chapter Overview 9.2. Forecast Methodology and Assumptions 9.3. Overall Diabetes Drug Delivery Devices Market, 2020-2030 9.3.1. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Type of Device 9.3.2. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Route of Administration 9.3.3. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Diabetes Type 9.3.4. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Device Usability 9.3.5. Diabetes Drug Delivery Devices Market, 2020-2030: Geographical Distribution 22.214.171.124. Diabetes Drug Delivery Devices Market in North America, 2020-2030 126.96.36.199. Diabetes Drug Delivery Devices Market in Europe, 2020-2030 188.8.131.52. Diabetes Drug Delivery Devices Market in Asia Pacific, 2020-2030 184.108.40.206. Diabetes Drug Delivery Devices Market in Rest of the World, 2020-2030 10\. CONCLUDING REMARKS 10.1. Chapter Overview 10.2. Key Takeaways 11\. EXECUTIVE INSIGHTS 12\. APPENDIX 1: TABULATED DATAFor more information about this report visit https://www.researchandmarkets.com/r/ia6njgResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900